Research Paper



Journal of Chemical Research

sagepub.com/journals-permissions

**NH**<sub>4</sub>I-mediated sp<sup>3</sup> C-H cross-dehydrogenative coupling of benzylamines with 2-methylquinoline for the synthesis of *E*-2-styrylquinolines

DOI: 10.1177/17475198211019253 journals.sagepub.com/home/chl

© The Author(s) 2021 Article reuse guidelines:

Xue Li<sup>1</sup><sup>(b)</sup>, Bin Huang<sup>1</sup>, JiangWei Wang<sup>2</sup>, YuanYuan Zhang<sup>1</sup> and WeiBo Liao<sup>1</sup>

#### Abstract

Without any metal catalyst, a simple and efficient method for the synthesis of E-2-styrylquinolines through sp<sup>3</sup> C-H crossdehydrogenative coupling of benzylamines with 2-methylquinolines mediated by  $NH_4I$  under air is successfully developed. The oxidative olefination proceeded through deamination and sp<sup>3</sup> C–H bond activation. A plausible mechanism is proposed for the construction of E-2-styrylquinolines.

### **Keywords**

2-methylquinolines, benzylamines, E-2-styrylquinolines, NH<sub>4</sub>I, sp<sup>3</sup> C-H cross-dehydrogenative coupling

Date received: 4 March 2021; accepted: 4 May 2021



## Introduction

On account of their unique structures and reactivities, quinoline and its derivatives are widely utilized to prepare various biologically important compounds.<sup>1,2</sup> Among quinoline derivatives, E-2-styrylquinolines are typical bioactive compounds acting as potent HIV-1 integrase inhibitors,3-5 leukotriene receptor antagonists,67 and antiallergic drugs.8 The wide applications of E-2styrylquinolines have attracted considerable attention in synthetic chemistry. In the past 10 years, widely used methods for the synthesis of E-2-styrylquinolines have mainly involved the reactions of 2-methylquinolines with benzyl alcohols,<sup>9-12</sup> benzyl amines,<sup>9,13-15</sup> aldehydes,<sup>16-19</sup> N-benzylidene-4-methylbenzenesulfonamides<sup>20</sup> and (Scheme 1). In 2011, Qian et al.<sup>20</sup> disclosed that Fe(OAc)<sub>2</sub> promoted the reactions of 2-methylquinolines and N-benzylidene-4-methylbenzenesulfonamides by removing a molecule of p-toluenesulfonamide to give E-2styrylquinolines. In 2019, Liang et al.<sup>16</sup> reported that various 2-alkenylquinolines could be produced from

2-methylquinolines and aldehydes under the synergistic organocatalysis of 1,3-dimethylbarbituric acid/HOAc for 24 h. In 2020, Susanta et al.<sup>9</sup> reported that *E*-2-styrylquinolines could be prepared from 2-methylquinolines by reactions with primary alcohols or primary amines using the NaCl/TBHP oxidative system. In the same year, Zhang et al.<sup>10</sup> showed that reactions of 2-methylquinolines and primary alcohols catalyzed by  $MnO_2$  in the presence of KOH eliminated molecule of  $H_2O$  and were transformed into *E*-2-styrylquinolines. Nevertheless, these methods suffer from environmental and economic concerns as they

#### **Corresponding author:**

Xue Li, Drug Research Center, Traditional Chinese Medicine Institute of Jiangxi, Nanchang 330046, P.R. China. Email: m18702635626@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

<sup>&</sup>lt;sup>1</sup>Drug Research Center, Traditional Chinese Medicine Institute of Jiangxi, Nanchang, P.R. China

<sup>&</sup>lt;sup>2</sup>Jiangxi Provincial Hospital of Traditional Chinese medicine, Nanchang, P.R. China



Scheme I. Methods for the preparation of E-2-styrylquinolines.

utilize strong oxidants and transition-metal catalysts, which impede the applicability of these methods. To avoid these drawbacks, we successfully developed a method that involves deamination and sp<sup>3</sup> C-H cross-dehydrogenative coupling of 2-methylquinolines and benzylamines to give various *E*-2-styrylquinolines mediated by NH<sub>4</sub>I in moderate to good yields (30%–93%) with NMP (*N*-methyl-2pyrrolidone) as the solvent, without any other metal catalyst at 160 °C for 10 h (Scheme 1).

# **Results and discussion**

The 2-Methylquinoline (1a) and benzylamine (2a) were selected as model substrates to optimize the reaction conditions for the synthesis of E-2-styrylquinoline (3a). The effects of different catalysts, solvents, and temperatures were investigated. The results are summarized in Table 1. First, different additives such as NBS (*N*-bromosuccinimide), NIS (N-iodosuccinimide), TBAI (tetra-n-butylammonium iodide), NH<sub>4</sub>I, and KI were investigated and NH<sub>4</sub>I was found to be the best, affording a 52% yield of 3a (Table 1, entries 1-5). No product was formed in the absence of a catalyst, even on increasing the reaction temperature to 160 °C (Table 1, entry 6). Next, the solvent was optimized and NMP was found to be the best (Table 1, entries 4 and 7-9). With NMP as the solvent, the reaction temperature and time were further optimized. When the temperature was increased from 120-160 °C, the yield of 3a increased from 52% to 85% (Table 1, entries 4, 10, and 11), which indicated that the reaction proceeded best at 160 °C. To further improve the yield of 3a, increased reaction times of up to 24h at 160 °C were tested; however, the yield was not

	+	NH <sub>2</sub>	catalyst,	
1a	2a			3a
Entry	Additive	Solvent	Temp (°C)	Yield of <b>3a</b> (%) <sup>b</sup>
I	NBS	NMP	120	Trace
2	NIS	NMP	120	Trace
3	TBAI	NMP	120	10
4	NH₄I	NMP	120	52
5	KI	NMP	120	Trace
6	None	NMP	160	0
7	NH₄I	CH,CN	80	Trace
8	NH₄I	Toluene	110	Trace
9	NH₄I	DMSO	160	Trace
10	NH₄I	NMP	140	64
11	NH₄I	NMP	160	85
12 <sup>c</sup>	NH₄I	NMP	160	85
13 <sup>d</sup>	NH₄I	NMP	160	86
14 <sup>e</sup>	NH₄Ì	NMP	160	85
l 5 <sup>f</sup>	NH₄Ì	NMP	160	18
16 <sup>g</sup>	NH₄I	NMP	160	86

 Table I. Optimization of the reaction conditions for the synthesis of 3a.<sup>a</sup>

NBS: N-bromosuccinimide; NIS: N-iodosuccinimide; TBAI: tetra-nbutylammonium iodide; DMSO: dimethyl sulfoxide.

<sup>a</sup>Reaction conditions: 1a (1.0 mmol), 2a (3.0 mmol), catalyst (1.2 equiv), solvent (4 mL), in air, 10 h.

<sup>b</sup>lsolated yield.

Reaction time: 14h.

<sup>d</sup>Reaction time: 18h.

<sup>e</sup>Reaction time: 24 h.

<sup>f</sup>Under N<sub>2</sub>. <sup>g</sup>Under O<sub>2</sub>.

$R \xrightarrow{II} NH_{2} + NH_{2} \xrightarrow{NH_{4}I} R \xrightarrow{R} NH_{4}I \xrightarrow{R} $				
Entry	R	Product <sup>b</sup>	Yield (%) <sup>c</sup>	
I	( <b>I</b> a) H	3a	85	
2	( <b>Ib</b> ) 3-CH <sub>3</sub>	3b	73	
3	( <b>Ic</b> ) 3-Br	3с	80	
4	( <b>Id</b> ) 4-CH <sub>3</sub>	3d	61	
5	( <b>Ie</b> ) 4-Cl	3е	68	
6	( <b>If</b> ) 6-CH <sub>3</sub>	3f	82	
7	( <b>I</b> g) 6-Cl	3g	93	
8	( <b>Ih</b> ) 6-Br	3h	89	
9	( <b>Ii</b> ) 7-CH <sub>3</sub>	3i	83	
10	( <b>Ij</b> ) 7-Cl	Зј	90	
11	( <b>Ik</b> ) 7-Br	3k	87	
12	(II) 8-CH <sub>3</sub>	31	54	
13	( <b>Im</b> ) 8-Cl	3m	59	
14		3n N N	60	
15	( <b>1</b> o)	30 N	51	

**Table 2.** Substrate scope of various quinolines having sp<sup>3</sup> carbons in the oxidative cross-dehydrogenative coupling reaction.<sup>a</sup>

<sup>a</sup>Reaction condition: I (1.0 mmol), **2a** (3.0 mmol), NH<sub>4</sub>I (1.2 equiv), NMP (4 mL), air, 160 °C, 10 h. <sup>b</sup>Structures were confirmed by <sup>1</sup>H and <sup>13</sup>C nuclear magnetic resonance (NMR) spectroscopy. <sup>c</sup>Isolated yield based on I.

improved (Table 1, entries 11–14). The optimum reaction time was therefore about 10 h (Table 1, entry 11). When the reaction was carried out under N<sub>2</sub>, the yield of **3a** decreased dramatically (Table 1, entry 15), which indicated that the mixture required the presence of O<sub>2</sub> or air. Subsequently, the reaction was carried out under an O<sub>2</sub> atmosphere and the yield of target product **3a** was found to be almost equal to the yield in air (Table 1, entries 11 and 16). So the optimal reaction conditions were established as follows: using NH<sub>4</sub>I as the additive, NMP as the solvent, 160 °C, 10 h.

With optimized conditions in hand, we set out to explore the substrate scope of various quinolines having sp3 carbons for oxidative cross-dehydrogenative coupling reactions. The target products 3 were obtained in moderate to good yields ranging from 51% to 93% by reacting quinolines 1 with benzylamine (2a) in NMP under air at 160 °C for 10h. The results are shown in Table 2. The nature of the substituents on substrates 1 affected the reaction yields to some degree. Both halogen-substituted and methyl-substituted 2-methylquinoline smoothly afforded the corresponding products in 54%–93% yields (Table 2, entries 2-12). Among them, when substituents were attached to C-3, C-4, C-6, C-7, or C-8, the yields of the halogen-substituted products were slightly higher than those of the methyl-substituted products. Notably, dimethyl-substituted quinolines only offered the products of olefination at the 2-methyl position, the methyls attached

at other positions were unreactive (Table 2, entries 2, 4, 6, 9, and 12). Besides, 2-methylquinoxaline and 1-methylisoquinoline also exhibited excellent reactivity with benzylamine (**2a**) under the standard conditions and gave the olefination products **3n** in 60% and **3o** in 51% yields (Table 2, entries 14 and 15).

Subsequently, we set out to examine the substrate scope of various methanamines 2 in reactions with 2-methylquinoline (1a). The target products 3 were obtained in good vields ranging from 30% to 90% under the optimized conditions. The results are shown in Table 3. The nature of different R groups of benzylamines 2 affected the reaction yields slightly. Halogen-substituted benzylamines and methyl-substituted benzylamines reacted with 1a to afford the corresponding olefination products in 72%-90% yields (Table 2, entries 1–8). It is worth noting that naphthalen- $\alpha$ methanamine (2i) provided the desired product 3x in excellent yield 88% (Table 2, entry 9). Besides, a heterocyclic methanamine such as 2-thiophene-methanamine (2j) and an aliphatic amine such as cyclohexyl methanamine (2k) also underwent deamination and were transformed effectively into the corresponding products 3y and 3z in yields of 73% and 30%, respectively (Table 2, entries 10 and 11). According to the <sup>1</sup>H nuclear magnetic resonance (NMR) spectra of olefination products 3 and earlier studies,<sup>14–16</sup> we were able to conform the (E)-configurations of the olefination products 3.



Table 3. Substrate scope of various primary amines.<sup>a</sup>

To further explore the mechanism of oxidative olefination for the construction of *E*-2-styrylquinolines, several control experiments were carried out. First, when adding the radical scavenger TEMPO (1.0 equiv) to the standard reaction, **3a** could be afforded in 84% yield (Scheme 2(a)), which suggested that the reaction may not proceed through a radical intermediate. Second, when **2a** alone was subjected to the standard reaction conditions, 30% yield of phenylmethanimine, 10% yield of *N*-benzylbenzamide, and a trace amount of benzaldehyde were observed (Scheme 2(b)). Finally, when **1a** reacted with phenylmethanimine under the standard conditions, an 86% yield of **3a** was obtained (Scheme 2(c)), suggesting that phenylmethanimine might be an intermediate in this reaction.

Based on these observations and related references,<sup>13,15</sup> a plausible mechanism is proposed in Scheme 3. Initially,  $NH_4I$  is oxidized to a highly active "I<sup>+</sup>" species in air. Second, the benzylamine is transformed into a phenylmethanimine by elimination under the influence of "I<sup>+</sup>." Finally, phenylmethanimine is attacked by the 2-methylquinoline and is transformed into the corresponding ole-fination product *via* elimination of a molecule of  $NH_3$ .

# Conclusion

In summary, we have developed an efficient approach for the synthesis of a variety of *E*-2-styrylquinolines through  $sp^3$  C-H cross-dehydrogenative coupling of benzylamines with 2-methylquinolines promoted by NH<sub>4</sub>I under air without any metal catalyst. The approach provides relatively mild reaction conditions, moderate to good yields, and encompasses a broad substrate scope. A plausible mechanism has been proposed for the oxidative olefination through deamination.

# **Experimental**

Infrared spectra were determined on a Nicolet Avatar-370 spectrometer in KBr ( $\nu$  in cm<sup>-1</sup>). Melting points were measured on a Büchi B-540 capillary melting point apparatus and are uncorrected. Mass spectra (ESI-MS) were recorded on a Thermo Finnigan LCQ-Advantage spectrometer. High-resolution mass spectra (ESI-HRMS) were obtained using an Agilent 6210 TOF instrument. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Varian Mercury Plus-400 spectrometer (400 and 100 MHz),  $\delta$  in parts per million, *J* in Hertz, using TMS as the internal standard. Signal multiplicities are assigned as singlet (s), doublet (d), multiplet (m). All analytical reagents were commercially available and were used directly without further purification.

# Synthesis of E-2-styrylquinolines (**3a** selected as an example); general procedure

A mixture of 2-methylquinoline (1a) (0.14 g, 1 mmol), benzylamine (0.32 g, 3.0 mmol), and  $NH_4I$  (0.17 g, 1.2 mmol) in NMP (4 mL) was stirred at 160 °C for 10h until the total

<sup>&</sup>lt;sup>a</sup>Reaction condition: **Ia** (1.0 mmol), **2** (3.0 mmol), NH<sub>4</sub>I (1.2 equiv), NMP (4 mL), air, 160 °C, 10 h. <sup>b</sup>Structures were confirmed by <sup>1</sup>H and <sup>13</sup>C nuclear magnetic resonance (NMR) spectroscopy. <sup>c</sup>Isolated yield based on **Ia**.



Scheme 2. Control experiments.



Scheme 3. A plausible mechanism.

consumption of **1a**. After cooling, the reaction mixture was washed with brine (20 mL) and extracted with  $CH_2Cl_2$  (2 × 20 mL). The combined organic extract was dried over  $Na_2SO_4$  and concentrated under vacuum. The residue was purified by column chromatography (petroleum ether/ EtOAc=6:1) to afford the target product **3a** (pale yellow solid, 85%, 0.20 g).

2-[(1E)-2-phenylethenyl]quinoline (**3a**). Pale yellow solid; 85%, 0.20 g; m.p. 91–92 °C (Lit.<sup>21</sup> 91–93 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.14–8.06 (m, 2H), 7.76 (d, J=8.2 Hz, 1H), 7.74–7.64 (m, 5H), 7.55–7.46 (m, 1H), 7.43–7.38 (m, 3H), 7.34–7.30 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.4, 148.2, 136.6, 136.3, 134.5, 129.7, 129.3, 129.0, 128.9, 128.6, 127.6, 127.5, 127.2, 126.3, 118.9. MS (ESI): m/z (%)=232.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>14</sub>N: 232.1126, found: 232.1133.

**3-***Methyl*-2-*[(1E)*-2-*phenylethenyl]quinoline* **(3b)**. Pale yellow solid; 73%, 0.18 g; m.p. 98–100 °C (Lit.21 98–100 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.09 (d, *J*=8.4 Hz, 1H), 8.02 (d, *J*=15.6 Hz, 1H), 7.88 (s, 1H), 7.72–7.63 (m, 4H), 7.51 (d, *J*=15.6 Hz, 1H), 7.47–7.39 (m, 3H), 7.35–7.32 (m, 1H), 2.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =154.9, 146.9, 137.1, 136.2, 135.6, 129.4, 129.1, 128.7, 128.6, 128.5, 127.8, 127.5, 126.7, 125.8, 124.3, 19.6. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 246.1283, found: 246.1290.

**3-Bromo-2-***[*(*IE*)-2-phenylethenyl]quinoline (**3c**). Pale yellow solid; 80%, 0.25 g; m.p. 103–105 °C (Lit.21 103–105 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.37 (s, 1H), 8.08–8.03 (m, 2H), 7.80 (d, *J*=15.6 Hz, 1H), 7.73–7.67 (m, 4H), 7.50 (t, *J*=7.3 Hz, 1H), 7.45–7.40 (m, 2H), 7.37–7.32 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =152.9, 147.0, 139.1, 136.9, 136.6, 130.1, 129.2, 128.9, 128.6, 128.4, 127.7, 126.8, 126.5, 124.8, 118.3. MS (ESI): m/z (%)=310.0 ([M]<sup>+</sup>, 51), 312.0([M]<sup>+</sup>, 49). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN: 310.0231, found: 310.0239; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN: 312.0211, found: 312.0218.

**4-Methyl-2-**[(*IE*)-2-phenylethenyl]quinoline<sup>15</sup> (**3d**). Pale yellow solid; 61%, 0.15 g; m.p. 122–124 °C (Lit.<sup>15</sup> 122–123 °C). 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.04 (d, *J*=8.0 Hz, 1H), 7.75 (d, *J*=8.0 Hz, 1H), 7.56–7.47 (m, 4H), 7.37–7.32 (m, 2H), 7.28–7.24 (m, 3H), 7.22–7.17 (m, 1H), 2.61(s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.0, 148.2, 144.3, 136.8, 134.2, 129.8, 129.5, 129.2, 128.8, 128.5, 127.5, 127.3, 125.9, 123.7, 119.8, 19.2. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 246.1283, found: 246.1291.

**4-Chloro-2-***[*(*IE*)-2-phenylethenyl]quinoline (**3e**). Pale yellow solid; 68%, 0.18 g; m.p. 109–111 °C (Lit.<sup>21</sup> 110–111 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.19–8.16 (m, 1H), 8.09 (d, *J*=8.4 Hz, 1H), 7.77–7.72 (m, 2H), 7.69–7.63 (m, 3H), 7.60–7.56 (m, 1H), 7.43–7.37 (m, 2H), 7.36–7.31 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.1, 149.2, 142.7, 136.2, 135.3, 130.5, 129.5, 128.9, 128.7, 127.9, 127.3,

127.0, 125.3, 124.0, 119.0. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for  $C_{17}H_{13}^{35}$ ClN: 266.0736, found: 266.0743;  $C_{17}H_{13}^{37}$ ClN: 268.0707, found: 268.0716.

6-Methyl-2-[(1E)-2-phenylethenyl]quinoline (**3f**). Pale yellow solid; 82%, 0.20 g; m.p. 141–143 °C (Lit.<sup>21</sup> 142–144°C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.11 (d, *J*=8.4 Hz, 1H), 7.97 (d, *J*=8.8 Hz, 1H), 7.67–7.62 (m, 4H), 7.55–7.53 (m, 2H), 7.43–7.38 (m, 3H), 7.34–7.31 (m, 1H), 2.49 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =155.3, 146.2, 136.9, 136.2, 135.7, 133.9, 132.0, 129.2, 128.8, 128.6, 128.5, 127.3, 127.2, 126.4, 118.9, 21.7. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 246.1283, found: 246.1290.

**6-Chloro-2-***[*(*IE*)-2-phenylethenyl]*quinoline* (**3g**). White solid; 93%, 0.25 g; m.p. 147–149 °C (Lit.<sup>21</sup> 148–149°C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.09 (d, *J*=8.8 Hz, 1H), 8.03 (d, *J*=9.0 Hz, 1H), 7.80–7.78 (m, 1H), 7.72–7.61 (m, 5H), 7.43–7.31 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.4, 146.3, 136.6, 135.5, 134.8, 131.7, 130.7, 130.5, 128.9, 128.6, 128.5, 127.8, 127.3, 126.2, 120.0. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>CIN: 266.0736, found: 266.0744; C<sub>17</sub>H<sub>13</sub><sup>37</sup>CIN: 268.0707, found: 268.0715.

**6-Bromo-2-[**(*IE*)-2-phenylethenyl]quinoline (**3h**). Pale yellow solid; 89%, 0.28 g; m.p. 164–166 °C (Lit.<sup>21</sup> 164–166 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.11 (d, *J*=8.6Hz, 1H), 8.05–7.98 (m, 2H), 7.71–7.68 (m, 1H), 7.69–7.61 (m, 4H), 7.42–7.31 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.6, 147.0, 136.6, 135.5, 135.0, 133.0, 130.8, 129.5, 128.9, 128.8, 128.5, 128.4, 127.3, 120.5, 119.5. MS (ESI): m/z (%)=310.0 ([M]<sup>+</sup>, 51), 312.0 ([M]<sup>+</sup>, 49). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN: 310.0231, found: 310.0238; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN: 312.0211, found: 312.0219.

7-Methyl-2-[(1E)-2-phenylethenyl]quinoline (**3i**). Pale yellow solid; 83%, 0.20 g; m.p. 106–108 °C (Lit.<sup>21</sup> 106–108 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.11 (d, *J*=8.6 Hz, 1H), 7.89–7.86 (m, 1H), 7.66–7.59 (m, 5H), 7.41–7.35 (m, 3H), 7.32–7.29 (m, 2H), 2.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.2, 148.6, 140.0, 136.2, 136.0, 134.1, 129.1, 128.8, 128.5, 128.4, 128.2, 127.3, 127.1, 125.5, 118.0, 21.9. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 246.1283, found: 246.1291.

7-*C*hloro-2-*[*(*1E*)-2-*p*henylethenyl]*quinoline* (**3***j*). Pale yellow solid; 90%, 0.24 g; m.p. 118–120 °C (Lit.<sup>21</sup> 118–119°C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =7.98–7.97 (m, 2H), 7.82 (d, *J*=8.2 Hz, 1H), 7.80–7.74 (m, 5H), 7.50–7.47 (m, 1H), 7.40–7.37 (m, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.7, 148.5, 136.3, 136.0, 135.6, 135.0, 128.9, 128.7, 128.6, 128.4, 128.1, 127.4, 127.0, 125.6, 119.3. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>CIN: 266.0736, found: 266.0742; C<sub>17</sub>H<sub>13</sub><sup>37</sup>CIN: 268.0707, found: 268.0717.

7-Bromo-2-[(1E)-2-phenylethenyl]quinoline (**3k**). Pale yellow solid; 87%, 0.27 g; m.p. 127–129 °C (Lit.<sup>14</sup> 127–129 °C).<sup>14</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.22 (d, *J*=1.6 Hz, 1H), 8.08 (d, *J*=8.8 Hz, 1H), 7.79–7.74 (m, 5H), 7.65–7.62 (m, 1H), 7.41–7.32 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.8, 148.7, 136.4, 136.2, 135.2, 131.7, 129.6, 128.9, 128.8, 128.7, 128.4, 127.5, 125.8, 123.8, 119.6. MS (ESI): m/z (%)=310.0 ([M]<sup>+</sup>, 51), 312.0 ([M]<sup>+</sup>, 49). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>79</sup>BrN: 310.0231, found: 310.0238; C<sub>17</sub>H<sub>13</sub><sup>81</sup>BrN: 312.0211, found: 312.0219.

**8**-Methyl-2-[(*IE*)-2-phenylethenyl]quinoline (**3**I). Pale yellow solid; 54%, 0.13 g; m.p. 72–73 °C (Lit.<sup>21</sup> 72°C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.05 (d, *J*=8.6Hz, 1H), 7.76 (d, *J*=16.2Hz, 1H), 7.68–7.62 (m, 4H), 7.56 (d, *J*=6.7Hz, 1H), 7.43–7.31 (m, 5H), 2.76 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =154.7, 147.2, 137.1, 136.7, 136.3, 133.7, 129.7, 129.4, 128.7, 128.4, 127.2, 127.1, 125.8, 125.3, 119.2, 18.4. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 246.1283, found: 246.1289.

8-*Chloro-2-[(1E)-2-phenylethenyl]quinoline* (**3m**). Pale yellow solid; 59%, 0.16 g; m.p. 88–90 °C (Lit.<sup>16</sup> 88–90 °C).<sup>16</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.11 (d, *J*=8.3 Hz, 1H), 7.80–7.75 (m, 2H), 7.64–7.68 (m, 4H), 7.47–7.31 (m, 5H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.8, 144.3, 136.6, 136.4, 135.2, 133.1, 129.7, 128.8, 128.7, 128.4, 127.3, 127.1, 126.4, 125.8, 119.6. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>CIN: 266.0736, found: 266.0745; C<sub>17</sub>H<sub>13</sub><sup>37</sup>CIN: 268.0707, found: 268.0715.

2-[(1E)-2-phenylethenyl]quinoxaline (**3n**). Pale yellow solid; 60%, 0.14 g; m.p. 101–103 °C (Lit.<sup>21</sup> 101–103 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =9.01 (s, 1H), 8.08 (d, J=7.9 Hz, 2H), 7.88 (d, J=16.3 Hz, 1H), 7.75–7.62 (m, 4H), 7.44–7.33 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =150.4, 144.7, 142.4, 141.6, 136.6, 135.9, 130.0, 129.4, 129.3, 129.2, 129.1, 128.9, 127.4, 125.1. MS (ESI): m/z (%)=233.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 233.1079, found: 233.1086.

*I*-[(*IE*)-2-phenylethenyl]isoquinoline (**3o**). Pale yellow solid; 51%, 0.12 g; m.p. 97–99 °C (Lit.<sup>21</sup> 97–98 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.58 (d, *J*=5.6Hz, 1H), 8.36 (d, *J*=8.5Hz, 1H), 8.01 (d, *J*=1.2Hz, 2H), 7.83 (d, *J*=7.8Hz, 1H), 7.72–7.66 (m, 3H), 7.65–7.62 (m, 1H), 7.57 (d, *J*=5.5Hz, 1H), 7.44–7.41 (m, 2H), 7.35–7.32 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =154.6, 142.7, 136.9, 136.7, 135.8, 129.9, 128.7, 128.6, 127.4, 127.3, 127.1, 126.7, 124.5, 122.8, 119.7. MS (ESI): m/z (%)=232.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>14</sub>N: 232.1126, found: 232.1134.

2-[(1E)-2-(2-Methyl)-phenylethenyl]quinoline (**3p**). Pale yellow solid; 89%, 0.22 g; m.p. 69–71 °C (Lit.<sup>22</sup> 69–71 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.30 (d, J=8.4 Hz, 1H), 8.06–8.01 (m, 2H), 7.98–7.92 (m, 2H), 7.83–7.77 (m, 2H), 7.60–7.57 (m, 1H), 7.37 (d, J=16.2 Hz, 1H), 7.27–7.21 (m, 3H), 2.48 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.4,

148.2, 136.9, 136.8, 135.2, 131.9, 131.0, 130.4, 130.3, 129.1, 129.0, 128.2, 127.6, 126.9, 126.7, 126.2, 120.5, 20.0. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for  $C_{18}H_{16}N$ : 246.1283, found: 246.1291.

2-[(1E)-2-(2-Chloro)-phenylethenyl]quinoline (**3q**). Pale yellow solid; 72%, 0.19 g; m.p. 78–80 °C (Lit.22 78–80 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.35 (d, *J*=8.4 Hz, 1H), 8.11 (d, *J*=16.2 Hz, 1H), 8.06–7.98 (m, 2H), 7.95 (d, *J*=8.0 Hz, 1H), 7.83–7.76 (m, 2H), 7.60–7.53 (m, 3H), 7.44–7.37 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =155.6, 148.2, 137.3, 134.2, 133.4, 132.0, 130.5, 130.4, 130.3, 129.4, 129.2, 128.3, 128.1, 127.8, 127.7, 126.9, 121.0. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>ClN: 266.0736, found: 266.0744; C<sub>17</sub>H<sub>13</sub><sup>37</sup>ClN: 268.0707, found: 268.0715.

2-[(1E)-2-(3-Methyl)-phenylethenyl]quinoline (**3r**). Pale yellow solid; 76%, 0.19g; m.p. 68–69 °C (Lit.<sup>22</sup> 68–69 °C).<sup>22</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.33 (d, J=8.4 Hz, 1H), 8.10 (d, J=16.2 Hz, 1H), 8.04–7.95 (m, 3H), 7.83 (d, J=8.4 Hz, 1H), 7.81–7.78 (m, 1H), 7.40–7.33 (m, 3H), 7.24–7.16 (m, 2H), 2.34 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.4, 148.2, 138.3, 136.9, 135.6, 132.1, 131.2, 130.5, 130.3, 129.2, 129.0, 128.3, 127.5, 126.7, 126.5, 126.2, 120.7, 21.1. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N: 246.1283, found: 246.1292.

2-[(1E)-2-(3-Fluoro)-phenylethenyl]quinoline (3s). Yellow solid; 83%, 0.21 g; m.p. 91–93 °C (Lit.<sup>16</sup> 91–93 °C).<sup>16</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.12 (d, J=8.4 Hz, 1H), 8.07–48.0 (m, 1H), 7.72–7.67 (m, 2H), 7.58–7.53 (m, 2H), 7.52–7.46 (m, 1H), 7.41–317 (m, 4H), 7.01 (t, J=8.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =163.1 (d, J=243 Hz), 155.2, 148.1, 138.8 (d, J=8 Hz), 136.3, 132.9 (d, J=3 Hz), 130.2, 130.0, 129.6, 129.1, 127.4, 127.3, 126.1, 123.1 (d, J=3 Hz), 119.3, 115.2 (d, J=21 Hz), 113.3 (d, J=22 Hz). MS (ESI): m/z (%)=250.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>FN: 250.1032, found: 250.1039.

2-[(1E)-2-(3-Chloro)-phenylethenyl]quinoline (3t). Yellow solid; 87%, 0.23 g; m.p. 90–92 °C (Lit.<sup>21</sup> 90–91 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.16 (d, *J*=8.5 Hz, 1H), 8.08 (d, *J*=8.4 Hz, 1H), 7.79–37.7 (m, 2H), 7.64–7.61 (m, 3H), 7.53–7.49 (m, 2H), 7.38 (d, *J*=16.2 Hz, 1H), 7.34–7.29 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =155.6, 148.2, 138.4, 136.5, 134.6, 132.8, 130.2, 130.1, 129.8, 129.3, 128.4, 127.5, 127.3, 127.0, 126.4, 125.4, 119.6. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>CIN: 266.0736, found: 266.0742; C<sub>17</sub>H<sub>13</sub><sup>37</sup>CIN: 268.0707, found: 268.0715.

2-[(1E)-2-(4-Methyl)-phenylethenyl]quinoline (**3u**). Yellow solid; 90%, 0.22 g; m.p. 110–112 °C (Lit.<sup>16</sup> 110–112 °C).<sup>16</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.08 (m, 2H), 7.77–7.66 (m, 4H), 7.55 (d, *J*=8.2Hz, 2H), 7.46 (t, *J*=7.4Hz, 1H), 7.38 (d, *J*=16.2Hz, 1H), 7.22 (d, *J*=7.9Hz, 2H), 2.35 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.3, 148.2, 138.6,

136.3, 134.5, 133.6, 129.6, 129.3, 129.0, 127.9, 127.5, 127.2, 127.1, 126.2, 119.1, 21.2. MS (ESI): m/z (%)=246.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for  $C_{18}H_{16}N$ : 246.1283, found: 246.1292.

2-[(1E)-2-(4-Fluoro)-phenylethenyl]quinoline (**3v**). Yellow solid; 86%, 0.21 g; m.p. 120–122 °C (Lit.<sup>16</sup> 120–122 °C).<sup>21</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.10–8.06 (m, 2H), 7.78 (d, *J*=8.2 Hz, 1H), 7.74–637 (m, 5H), 7.56–7.49 (m, 1H), 7.32 (d, *J*=16.2 Hz, 1H), 7.13–77.0 (m, 2H).<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 163.0 (d, *J*=246 Hz), 155.9, 148.3, 136.3, 133.4, 132.8 (d, *J*=3 Hz), 129.8, 129.2, 128.9, 128.6 (d, *J*=3 Hz), 127.6, 127.3, 126.4, 119.6, 115.9 (d, *J*=22 Hz). MS (ESI): m/z (%)=250.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub>FN: 250.1032, found: 250.1040.

2-[(1E)-2-(4-Chloro)-phenylethenyl]quinoline (**3w**). Yellow solid; 80%, 0.21 g; m.p. 141–143 °C (Lit.<sup>16</sup> 141–142 °C).<sup>16</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.09 (d, J=8.4 Hz, 2H), 7.77 (d, J=8.0 Hz, 1H), 7.72–7.68 (m, 1H), 7.65–87.5 (m, 2H), 7.55–67.4 (m, 3H), 7.36–17.3 (m, 3H).<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =155.7, 148.3, 136.3, 135.1, 134.2, 132.8, 129.8, 129.5, 129.1, 128.9, 128.4, 127.5, 127.4, 126.2, 119.2. MS (ESI): m/z (%)=266.1 ([M]<sup>+</sup>, 75), 268.1 ([M]<sup>+</sup>, 25). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>13</sub><sup>35</sup>CIN: 266.0736, found: 266.0742; C<sub>17</sub>H<sub>13</sub><sup>37</sup>CIN: 268.0707, found: 268.0715.

2-[(1E)-2-(2-(Naphthalen-1-yl))vinyl]quinoline (**3x**). Yellow solid; 88%, 0.25 g; m.p. 104–106 °C (Lit.<sup>22</sup> 105–106 °C).<sup>17</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.50 (d, *J*=16.2 Hz, 1H), 8.32 (d, *J*=8.4 Hz, 1H), 8.12 (d, *J*=8.4 Hz, 2H), 7.86–7.71 (m, 6H), 7.56–7.45 (m, 5H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.2, 148.3, 136.2, 134.1, 133.7, 131.6, 131.5, 131.3, 129.6, 129.3, 128.8, 128.6, 127.5, 127.4, 126.3, 126.2, 125.8, 125.7, 124.1, 123.8, 119.5. MS (ESI): m/z (%)=282.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>21</sub>H<sub>16</sub>N: 282.1283, found: 282.1292.

2-[(1E)-2-(2-(Thiophen-2-yl))vinyl]quinoline (**3y**). Yellow solid; 73%, 0.17 g; m.p. 89–91 °C (Lit.<sup>17</sup> 89–91 °C).<sup>17</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.07–8.00 (m, 2H), 7.84 (d, J=16.2Hz, 1H), 7.77–7.72 (m, 2H), 7.56 (d, J=8.4Hz, 1H), 7.50–7.47 (m, 1H), 7.30–7.19 (m, 3H), 7.05–7.02 (m, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =155.6, 155.5, 148.2, 142.1, 136.2, 129.8, 129.1, 128.2, 128.0, 127.7, 127.4, 127.2, 126.0, 125.9, 119.2. MS (ESI): m/z (%)=238.1 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>15</sub>H<sub>12</sub>NS: 238.0690, found: 238.0697.

2-[(1E)-2-(2-Cyclohexylvinyl)]quinoline (**3**z). Pale yellow oil; 30%, 0.07 g.<sup>17</sup> 1H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ =8.07–8.02 (m, 2H), 7.76–7.72 (m, 1H), 7.68–7.63 (m, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.47–7.43 (m, 1H), 6.80–6.76 (m, 1H), 6.66 (d, J=16.2 Hz, 1H), 2.30–2.15 (m, 1H), 1.77–1.64 (m, 4H), 1.33–1.19 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ =156.6, 148.2, 143.5, 136.2, 129.4, 129.1, 128.5, 127.4, 127.2, 125.8, 118.6, 41.0, 32.3, 26.1, 26.0. MS (ESI): m/z (%)=238.2 ([M]<sup>+</sup>, 100). HRMS (ESI): m/z [M]<sup>+</sup> calcd for C<sub>17</sub>H<sub>20</sub>N: 238.1596, found: 238.1604.

## **Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We are grateful to the Traditional Chinese Medicine Research Projects of Health and Family Planning Commission of Jiangxi Province (No. 2019A228 and 2020B0388) for financial support.

## **ORCID** iD

Xue Li (i) https://orcid.org/0000-0002-9499-2033

#### References

- Yuan HB and Parrill AL. *Bioorg Med Chem* 2002; 10: 4169– 4183.
- 2. Solomon VR and Lee H. Curr Med Chem 2011; 18: 1488–1508.
- Bonnenfant S, Thomas CM, Vita C, et al. J Virol 2004; 78: 5728–5736.
- Mousnier A, Leh H, Mouscadet JF, et al. *Mol Pharmacol* 2004; 66: 783–788.
- 5. Polanski J, Zouhiri F, Jeanson L, et al. *M J Med Chem* 2002; 45: 4647–4654.
- Merschaert A, Boquel P, Van Hoeck JP, et al. Org Process Res Dev 2006; 10: 776–783.
- King AO, Corley EG, Anderson RK, et al. J Org Chem 1993; 58: 3731–3735.

- 8. Belley ML, Leger S, Labelle M, et al. Patent 5565473, 1996, USA.
- 9. Susanta H, Vikas T, Ashutosh V, et al. *Org Lett* 2020; 22: 5496–5501.
- 10. Zhang CY, Li ZH, Fang YC, et al. *Tetrahedron* 2020; 76: 130968.
- 11. Chandan C, Siddiki H and Ken-Ichi S. *Tetrahedron Lett* 2013; 54: 6490–6493.
- 12. Matteo S, Nieves C, Maria Laura B, et al. *Synlett* 2011; 17: 2577–2579.
- Sharma R, Abdullaha M and Bharate SB. *J Org Chem* 2017; 82: 9786–9793.
- Mao D, Zhu XY, Hong G, et al. Synlett 2016; 27: 2481– 2484.
- 15. Gong L, Xing LJ, Xu T, et al. *Org Biomol Chem* 2014; 12: 6557–6560.
- Liang E, Wang JQ, Wu YR, et al. *Adv Synth Catal* 2019; 361: 3619–3623.
- 17. Jamal Z, Teo YC and Lim GS. *Tetrahedron* 2016; 72: 2132–2138.
- Yaragorla S, Singh G and Dada R. *Tetrahedron Lett* 2015; 56: 5924–5929.
- Pi DW, Jiang K, Zhou HF, et al. RSC Adv 2014; 4: 57875– 57884.
- 20. Qian B, Xie P, Xie Y, et al. Org Lett 2011; 13: 2580-2583.
- 21. Zhang ZH, Pi C, Tong H, et al. Org Lett 2017; 19: 440– 443.
- 22. Xu LB, Shao ZZ, Wang L, et al. *Tetrahedron Lett* 2014; 50: 6856–6860.